Harvard Bioscience, Inc. (HBIO)

CIK 0001123494 · Healthcare · Medical Instruments & Supplies

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 8-K (2026-05-12) · 99.1
Latest FY-2025 8-K (2026-03-12) · 99.1  |  8-K (2026-02-10) · 99.1
Q3-2025 8-K (2025-11-06) · 99.1
Q2-2025 8-K (2025-08-11) · 99.1
Q1-2025 8-K (2025-05-12) · 99.1
FY-2024 8-K (2025-03-12) · 99.1
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-08) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023 8-K (2024-03-07) · 99.1  |  8-K (2024-01-05) · 99.1
Q3-2023 8-K (2023-11-07) · 99.1
Q2-2023 8-K (2023-08-08) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Condensed Consolidated Balance Sheets (current Period Unaudited
—
Condensed Consolidated Balance Sheets (current Period Unaudited)
—
Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (current Period Unaudited (P)
—
Condensed Consolidated Balance Sheets (current Period Unaudited) (P)
—
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Income (loss) (unaudited)
—
Consolidated Statements of Operations (P)
—
Consolidated Statements of Comprehensive Income (loss) (unaudited) (P)
—
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Comprehensive Loss (P)
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Stockholders' Equity (unaudited) (P)
—
Consolidated Statements of Cash Flows
Notes
Award Timing Disclosure
—
Cybersecurity Risk Management and Strategy Disclosure
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Note 1
Note 10
Note 11
Note 12
Note 13
Note 14
Note 15
Note 16
Note 17
—
Note 18
—
Note 19
—
Note 2
Note 20
—
Note 3
Note 4
Note 5
Note 6
Note 7
Note 8
Note 9